Hemocompatible Magnetic Nano-Adsorbents via α-, β-, and γ-Cyclodextrin Surface Functionalization

Introduction

Magnetic nanoparticles (MNPs) have garnered substantial attention in biomedical and environmental applications due to their ease of manipulation under magnetic fields and high surface-to-volume ratio. However, their interaction with biological systems is often complicated by non-specific protein adsorption and poor hemocompatibility. To overcome these challenges, surface modification with biocompatible molecules, such as cyclodextrins (CDs), has emerged as a promising strategy.

CDs, a family of cyclic oligosaccharides composed of glucopyranose units, have emerged as versatile modifiers for nanomaterials. Their unique toroidal structure features a hydrophilic exterior and a hydrophobic cavity, enabling host–guest interactions and surface shielding.

Synthesis and Functionalization of CD-Coated MNPs

The MNPs employedwere synthesized [1] via a co-precipitation method, followed by surface silanization using (3-aminopropyl)triethoxysilane (APTES) to introduce amino groups. Cyclodextrin functionalization was achieved through covalent coupling, forming stable CD-MNP hybrids with defined surface chemistry.

The choice of cyclodextrin type—α (6 glucose units), β (7 units), or γ (8 units)—affects not only the cavity size but also the surface architecture and hydration shell. These parameters critically influence protein adsorption and hemocompatibility.

Protein Adsorption and Corona Composition

Compared to bare MNPs, all CD-modified variants exhibited a marked reduction in total protein adsorption when normalized to surface area, underscoring the anti-fouling efficacy of CD coatings.

Interestingly, the identity and relative abundance of adsorbed proteins varied according to the CD type:

• α-CD-MNPs preferentially reduced fibrinogen binding, a key protein involved in thrombus formation and platelet adhesion.
• β-CD-MNPs suppressed complement protein C3 adsorption, which plays a central role in opsonization and immunogenic clearance.
• γ-CD-MNPs displayed a broadly suppressed adsorption profile, affecting multiple plasma proteins including plasminogen and Factor XI.

Hemocompatibility Assessment

Hemocompatibility testing was conducted under static and dynamic conditions using human whole blood and plasma. All CD-coated MNPs exhibited hemolytic indices below 2%, far below the acceptable clinical threshold (5%). Platelet activation levels remained statistically indistinguishable from negative controls, indicating negligible activation or aggregation. Furthermore, clotting assays including prothrombin time (PT), activated partial thromboplastin time (aPTT), and thrombin generation assays confirmed that CD-MNPs did not disrupt intrinsic or extrinsic coagulation pathways.

Notably, γ-CD-MNPs demonstrated the most balanced hemocompatibility, with minimal deviation across all blood-contact metrics, highlighting their potential as a universal blood-compatible surface.

Comparative Evaluation of α-, β-, and γ-CDs

The three cyclodextrin types conferred distinct biointerfaces on MNPs:

• α-CD-MNPs may be advantageous for applications where minimizing thrombotic risk is critical due to their low fibrinogen affinity.
• β-CD-MNPs, with reduced complement activation, may suit immunologically sensitive therapeutic platforms.
• γ-CD-MNPs appear optimal for general blood-contacting applications, providing uniform suppression of multiple hemotoxic markers.

Alfa Chemistry offers a comprehensive portfolio of cyclodextrins and related compounds, including α-, β-, and γ-cyclodextrins, tailored for research and industrial applications. Contact us today to learn how our products can support your innovation.

Related Products

It should be noted that our our products and services are for research use only, not for clinical use.